Fosamax and Osteonecrosis of the Jaw: Risk, Causation, and What Studies Show
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Information to Targeted Drug Safety
For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions and therapeutic interventions. This legacy heritage, rooted in the dissemination of broad clinical knowledge, has enabled patients and practitioners alike to navigate complex health landscapes with greater awareness. Within this tradition, the focus has often been on the benefits and risks of pharmaceutical treatments, emphasizing the importance of informed decision-making in routine medical care. As the archive of such information has evolved, it has increasingly recognized the need to address specific, rare adverse events that may arise from widely prescribed medications. This shift reflects a growing sophistication in how health information is contextualized, moving from general awareness to targeted scrutiny of drug safety profiles. In this vein, the transition from a broad health context to a more focused occupational exposure concern becomes necessary. While the general public may encounter pharmaceutical risks through prescription use, certain professional environments present unique exposure scenarios that warrant separate consideration. The pivot here is from the patient-centered understanding of medication side effects to the occupational health perspective, where sustained or heightened exposure to pharmaceutical agents in manufacturing or clinical settings may introduce distinct risk patterns. This transition sets the stage for examining how such exposures relate to specific health outcomes, without delving into mechanistic claims.
The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding points to the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate suppress bone turnover, which can impair the jawbone's ability to remodel and repair microdamage. A multiscale characterization of jawbone tissue has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structure and physiology of the jawbone—such as its high vascularity and constant mechanical stress from chewing—may make it particularly vulnerable to the effects of suppressed bone turnover. Additionally, known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
A cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This data supports a dose-response relationship, with longer exposure correlating with higher risk. Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), further supporting a causal link. The timeline between exposure and documented harm can range from months to years. The label notes that the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), but this likely refers to milder symptoms such as bone pain rather than ONJ itself. For ONJ, the risk increases with duration of exposure, with significant elevation after 2-3 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). The condition can also occur after drug discontinuation, as bisphosphonates have a long half-life in bone. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), suggesting that the risk is at least partially reversible.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how does it work?
Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?
Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. It has been reported in patients taking bisphosphonates, including Fosamax. The risk increases with longer treatment duration, and the condition may be partially reversible upon discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
What does the research say about the dose-response relationship between Fosamax and ONJ?
A cohort study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use. Absolute risks remain low (approximately 0.05% after 5 years) and diminish after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.